Unknown

Dataset Information

0

Hepatocyte-specific HIF-1? ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation.


ABSTRACT: The decrease in incretin effects is an important etiologic component of type 2 diabetes with unknown mechanisms. In an attempt to understand obesity-induced changes in liver oxygen homeostasis, we found that liver HIF-1? expression was increased mainly by soluble factors released from obese adipocytes, leading to decreased incretin effects. Deletion of hepatocyte HIF-1? protected obesity-induced glucose intolerance without changes in body weight, liver steatosis, or insulin resistance. In-depth mouse metabolic phenotyping revealed that obesity increased first-pass degradation of an incretin hormone GLP-1 with increased liver DPP4 expression and decreased sinusoidal blood flow rate, reducing active GLP-1 levels in peripheral circulation. Hepatocyte HIF-1? KO blocked these changes induced by obesity. Deletion of hepatocyte HIF-2? did not change liver DPP4 expression but improved hepatic steatosis. Our results identify a previously unknown pathway for obesity-induced impaired beta cell glucose response (incretin effects) and the development of glucose intolerance through inter-organ communications.

SUBMITTER: Lee YS 

PROVIDER: S-EPMC6609217 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation.

Lee Yun Sok YS   Riopel Matthew M   Cabrales Pedro P   Bandyopadhyay Guatam K GK  

Science advances 20190703 7


The decrease in incretin effects is an important etiologic component of type 2 diabetes with unknown mechanisms. In an attempt to understand obesity-induced changes in liver oxygen homeostasis, we found that liver HIF-1α expression was increased mainly by soluble factors released from obese adipocytes, leading to decreased incretin effects. Deletion of hepatocyte HIF-1α protected obesity-induced glucose intolerance without changes in body weight, liver steatosis, or insulin resistance. In-depth  ...[more]

Similar Datasets

| S-EPMC5171868 | biostudies-literature
| S-EPMC9898070 | biostudies-literature
| S-EPMC6061882 | biostudies-literature
| S-EPMC5604011 | biostudies-literature
| S-EPMC5454020 | biostudies-literature
| S-EPMC7458039 | biostudies-literature
| S-EPMC3486049 | biostudies-literature
| S-EPMC10140483 | biostudies-literature
| S-EPMC6821315 | biostudies-literature
| S-EPMC5703960 | biostudies-literature